Bath PM, et al. - In this multicentre, paramedic-delivered, ambulance-based, prospective, randomized, sham-controlled, blinded-endpoint, phase 3 trial, researchers estimated 1149 subjects to analyze the consequences of transdermal glyceryl trinitrate (GTN; also known as nitroglycerin), a nitric oxide donor administration very early after stroke onset. About 597 candidates had an ischaemic stroke, 145 had intracerebral hemorrhage, 109 had a transient ischaemic attack whereas 297 had a non-stroke mimic at the final diagnosis of the index event. They did not find any significant variation in the 7-level modified Rankin Scale (mRS) between the groups. They also noted no variation in secondary outcomes like death (treatment-related deaths: 36 in the GTN group vs 23 in the sham group), grave unfavorable incidents (188 in the GTN group vs 170 in the sham group) between the treatment groups.